Literature DB >> 12483538

YY1 and NF-Y binding sites regulate the transcriptional activity of the dek and dek-can promoter.

Kajal V Sitwala1, Kristine Adams, David M Markovitz.   

Abstract

The mammalian protein DEK has been implicated in multiple cellular processes, including transcriptional regulation, mRNA processing, and chromatin remodeling, and is associated with a number of clinical autoimmune and neoplastic conditions. The connection between DEK and cancer exists at multiple levels: (a) the t(6;9) chromosomal translocation that characterizes a subtype of acute myelogenous leukemia cases results in the formation of a DEK-CAN fusion oncoprotein; (b) a fragment of dek cDNA is capable of partially reversing the radiation-sensitive phenotype of fibroblasts cultured from ataxia-telangiectasia patients; and (c) increased levels of dek mRNA have been found to be associated with hepatocellular carcinoma, glioblastoma, and melanoma. Despite the growing list of cancer subtypes with a connection to DEK, the factors that mediate its expression have yet to be characterized. Here we undertake the analysis of DEK regulation by mapping the discrete elements within the proximal promoter that are responsible for constitutive transcription of dek in transformed cells. We find that functional elements include an inverted CCAAT box and a YY1 consensus binding site, and the introduction of point mutations into these sites markedly diminishes transcriptional activity. In addition, we identify the transcriptional activator NF-Y as a member of the CCAAT-binding complex, and verify binding of the transcription factor YY1 at its consensus site in the dek promoter. The discovery of NF-Y and YY1 as regulatory determinants of DEK expression is consistent with the well-documented roles of these two factors in cellular proliferation and transformation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12483538     DOI: 10.1038/sj.onc.1206041

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Functional domains of the ubiquitous chromatin protein DEK.

Authors:  Ferdinand Kappes; Ingo Scholten; Nicole Richter; Claudia Gruss; Tanja Waldmann
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

Review 2.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

3.  Development of a malignancy-associated proteomic signature for diffuse large B-cell lymphoma.

Authors:  Paul B Romesser; David H Perlman; Douglas V Faller; Catherine E Costello; Mark E McComb; Gerald V Denis
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

Review 4.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

5.  Apoptosis inhibition by the human DEK oncoprotein involves interference with p53 functions.

Authors:  Trisha M Wise-Draper; Hillary V Allen; Elizabeth E Jones; Kristen B Habash; Hiroshi Matsuo; Susanne I Wells
Journal:  Mol Cell Biol       Date:  2006-08-07       Impact factor: 4.272

6.  The human DEK proto-oncogene is a senescence inhibitor and an upregulated target of high-risk human papillomavirus E7.

Authors:  Trisha M Wise-Draper; Hillary V Allen; Megan N Thobe; Elizabeth E Jones; Kristen B Habash; Karl Münger; Susanne I Wells
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

7.  DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.

Authors:  F Kappes; J Fahrer; M S Khodadoust; A Tabbert; C Strasser; N Mor-Vaknin; M Moreno-Villanueva; A Bürkle; D M Markovitz; E Ferrando-May
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

Review 8.  Concise review: role of DEK in stem/progenitor cell biology.

Authors:  Hal E Broxmeyer; Nirit Mor-Vaknin; Ferdinand Kappes; Maureen Legendre; Anjan K Saha; Xuan Ou; Heather O'Leary; Maegan Capitano; Scott Cooper; David M Markovitz
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

9.  A BMPR2/YY1 Signaling Axis Is Required for Human Cytomegalovirus Latency in Undifferentiated Myeloid Cells.

Authors:  Emma Poole; Maria Cristina Carlan da Silva; Chris Huang; Marianne Perera; Sarah Jackson; Ian J Groves; Mark Wills; Amer Rana; John Sinclair
Journal:  mBio       Date:  2021-06-01       Impact factor: 7.867

10.  The DEK oncogene is a target of steroid hormone receptor signaling in breast cancer.

Authors:  Lisa M Privette Vinnedge; Shuk-Mei Ho; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.